{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T05:06:03Z","timestamp":1780031163156,"version":"3.53.1"},"reference-count":83,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The low-Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols (FODMAP) diet is widely used for irritable bowel syndrome (IBS), but response varies markedly across patients. This heterogeneity has shifted the field from testing average efficacy toward forecasting individual benefit and translating microbiome science into practical precision-nutrition tools.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We present a conceptual analysis grounded in evidence mapping from human IBS studies that paired dietary interventions (primarily low-FODMAP pathways) with baseline microbiome and\/or multi-omics measurements. Findings are organized within a \u201cmicrobiome-to-model\u201d roadmap that specifies responder endpoints, candidate data layers (taxa, functions, metabolites and volatile signatures), modeling choices, and the validation and implementation requirements needed for clinical decision support.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Three recurring signals emerge across cohorts. Baseline microbial ecology can stratify response, but taxonomic features alone often fail to transport across studies. Functional readouts, including metabolites and volatile signatures, are closer to symptom mechanisms and can improve interpretability; however, clinical deployment is still limited by endpoint heterogeneity, imperfect exposure and adherence measurement, batch effects, and insufficient external validation and calibration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IBS is well suited for microbiome-informed responder prediction, provided that models are developed with deployment in mind. Progress will depend on validation-first study designs, harmonized responder endpoints and adherence capture, robust multi-omics pipelines, and biologically interpretable decision rules that can be prospectively tested and monitored for temporal instability in real-world care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1809221","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:50:18Z","timestamp":1780030218000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Reframing precision nutrition in irritable bowel syndrome: a mechanism-informed conceptual framework for responder prediction and clinical translation"],"prefix":"10.3389","volume":"17","author":[{"given":"Ya","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Tuina, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Tuina, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhou","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Tuina, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijia","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Tuina, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Tuina, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuquan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Tuina, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juntao","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Tuina, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Tuina, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anning","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Tuina, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.03.035","article-title":"Rome IV\u2014functional GI disorders: disorders of gut\u2013brain interaction","volume":"150","author":"Drossman","year":"2016","journal-title":"Gastroenterology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.5056\/jnm16214","article-title":"What is new in rome IV","volume":"23","author":"Schmulson","year":"2017","journal-title":"J Neurogastroenterol Motil"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1053\/j.gastro.2016.02.032","article-title":"Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV","volume":"150","author":"Drossman","year":"2016","journal-title":"Gastroenterology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1053\/j.gastro.2020.04.014","article-title":"Worldwide prevalence and burden of functional gastrointestinal disorders, results of the Rome Foundation global study","volume":"160","author":"Sperber","year":"2021","journal-title":"Gastroenterology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-325214","article-title":"Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis","volume":"71","author":"Black","year":"2022","journal-title":"Gut"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.02.045","article-title":"Efficacy and acceptability of dietary therapies in non-constipated irritable bowel syndrome: a randomized trial of traditional dietary advice, the low FODMAP diet, and the gluten-free diet","volume":"21","author":"Staudacher","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1053\/j.gastro.2013.09.046","article-title":"A diet low in FODMAPs reduces symptoms of irritable bowel syndrome","volume":"146","author":"Halmos","year":"2014","journal-title":"Gastroenterology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1053\/j.gastro.2015.07.054","article-title":"Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial","volume":"149","author":"B\u00f6hn","year":"2015","journal-title":"Gastroenterology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3945\/jn.112.159285","article-title":"Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome","volume":"142","author":"Staudacher","year":"2012","journal-title":"J Nutr"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-325177","article-title":"Two microbiota subtypes identified in irritable bowel syndrome with distinct responses to the low FODMAP diet","volume":"71","author":"Vervier","year":"2022","journal-title":"Gut"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2022.2138672","article-title":"Artificial intelligence-based personalized diet: a pilot clinical study for irritable bowel syndrome","volume":"14","author":"Karakan","year":"2022","journal-title":"Gut Microbes"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002862","article-title":"A multicenter randomized controlled trial of microbiome-based artificial intelligence-assisted personalized diet vs low-fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet: a novel approach for the management of irritable bowel syndrome","volume":"119","author":"Tunali","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1046\/j.1365-2036.1997.142318000.x","article-title":"The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress","volume":"11","author":"Francis","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.13","article-title":"Adequate relief in a treatment trial with IBS patients: a prospective assessment","volume":"104","author":"Passos","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2007.03.004","article-title":"Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints","volume":"5","author":"Camilleri","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B18","article-title":"Irritable bowel syndrome\u2014Clinical evaluation of drugs for treatment: guidance for industry","volume-title":"U.S. Food and drug administration","year":"2012"},{"key":"B19","article-title":"Guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome (Revision 1). CPMP\/EWP\/785\/97 Rev. 1; EMA\/CHMP\/60337\/2013","volume-title":"European medicines agency","year":"2014"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2036.2009.03951.x","article-title":"Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome consensus conference","volume":"29","author":"Gasbarrini","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2017.46","article-title":"Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American consensus","volume":"112","author":"Rezaie","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/ueg2.12133","article-title":"European guideline on indications, performance, and clinical impact of hydrogen and methane breath tests in adult and pediatric patients","volume":"10","author":"Hammer","year":"2022","journal-title":"United Eur Gastroenterol J"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1017\/S0029665124000075","article-title":"The low FODMAP diet in clinical practice: where are we and what are the long-term considerations","volume":"83","author":"Lomer","year":"2024","journal-title":"Proc Nutr Soc"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.434","article-title":"A diet low in fermentable oligo-, di-, and monosaccharides and polyols improves quality of life and reduces activity impairment in patients with irritable bowel syndrome and diarrhea","volume":"111","author":"Eswaran","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04237.x","article-title":"Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon","volume":"31","author":"Barrett","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2010.06370.x","article-title":"Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome","volume":"25","author":"Ong","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.70060","article-title":"Mediterranean diet versus low-FODMAP diet for non-constipated irritable bowel syndrome: a randomized controlled trial","volume":"37","author":"Singh","year":"2025","journal-title":"Neurogastroenterol Motil"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00045-1","article-title":"Efficacy of a low FODMAP diet, a low-carbohydrate diet, and pharmacological treatment in irritable bowel syndrome: a randomised clinical trial","volume":"9","author":"Nybacka","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1053\/j.gastro.2013.01.049","article-title":"A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function","volume":"144","author":"Vazquez-Roque","year":"2013","journal-title":"Gastroenterology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17239","article-title":"Randomised controlled trial: effects of gluten-free diet on symptoms and the gut microenvironment in irritable bowel syndrome","volume":"56","author":"Algera","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/nu13020416","article-title":"Assessment of a 4-week starch- and sucrose-reduced diet and its effects on gastrointestinal symptoms and inflammatory parameters among patients with irritable bowel syndrome","volume":"13","author":"Nilholm","year":"2021","journal-title":"Nutrients"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/nu14091688","article-title":"A starch- and sucrose-reduced diet in irritable bowel syndrome: effects on circulating inflammatory and metabolic mediators","volume":"14","author":"Roth","year":"2022","journal-title":"Nutrients"},{"key":"B33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.14309\/ajg.0000000000001036","article-title":"ACG clinical guideline: management of irritable bowel syndrome","volume":"116","author":"Lacy","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.105","article-title":"Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life","volume":"108","author":"B\u00f6hn","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00574.2004","article-title":"Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity","volume":"290","author":"Pimentel","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2014.250","article-title":"Effect of increased bile acid synthesis or fecal excretion in irritable bowel syndrome-diarrhea","volume":"109","author":"Camilleri","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.cgh.2012.05.006","article-title":"Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea","volume":"10","author":"Wong","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1053\/j.gastro.2022.02.016","article-title":"Mucosal serotonin reuptake transporter expression in irritable bowel syndrome is modulated by gut microbiota via a mast cell\u2013prostaglandin E2 pathway","volume":"162","author":"Gao","year":"2022","journal-title":"Gastroenterology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1053\/j.gastro.2021.12.243","article-title":"Bile acid diarrhea is associated with increased intestinal permeability compared with irritable bowel syndrome-diarrhea","volume":"162","author":"Magnus","year":"2022","journal-title":"Gastroenterology"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105282","article-title":"Microbiome-driven IBS metabotypes influence response to the low FODMAP diet: insights from the faecal volatome","volume":"107","author":"Conley","year":"2024","journal-title":"EBioMedicine"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058204","article-title":"An investigation of fecal volatile organic metabolites in irritable bowel syndrome","volume":"8","author":"Ahmed","year":"2013","journal-title":"PloS One"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2009.06.017","article-title":"Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome","volume":"146","author":"Zhou","year":"2009","journal-title":"Pain"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123498","article-title":"The intestinal barrier in irritable bowel syndrome","volume":"10","author":"Ludidi","year":"2015","journal-title":"PloS One"},{"key":"B44","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1053\/j.gastro.2003.11.055","article-title":"Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome","volume":"126","author":"Barbara","year":"2004","journal-title":"Gastroenterology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/j.gastro.2019.03.049","article-title":"Gut microbiota in patients with irritable bowel syndrome\u2014a systematic review","volume":"157","author":"Pittayanon","year":"2019","journal-title":"Gastroenterology"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318717","article-title":"No distinct microbiome signature of irritable bowel syndrome found in a Swedish random population","volume":"69","author":"Hugerth","year":"2020","journal-title":"Gut"},{"key":"B47","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1053\/j.gastro.2016.09.049","article-title":"Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome","volume":"152","author":"Tap","year":"2017","journal-title":"Gastroenterology"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/cells12020236","article-title":"Impaired intestinal permeability of tricellular tight junctions in patients with irritable bowel syndrome with mixed bowel habits (IBS-M)","volume":"12","author":"Awad","year":"2023","journal-title":"Cells"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9082403","article-title":"Usefulness of machine learning-based gut microbiome analysis for identifying patients with irritable bowel syndrome","volume":"9","author":"Fukui","year":"2020","journal-title":"J Clin Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"6818","DOI":"10.1038\/s41467-022-34405-3","article-title":"Faecal microbiome-based machine learning for multi-class disease diagnosis","volume":"13","author":"Su","year":"2022","journal-title":"Nat Commun"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17609","article-title":"Faecal and urine metabolites, but not gut microbiota, may predict response to low FODMAP diet in irritable bowel syndrome","volume":"58","author":"Wilson","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.13884","article-title":"Application of metabolomics to the study of irritable bowel syndrome","volume":"32","author":"Bennet","year":"2020","journal-title":"Neurogastroenterol Motil"},{"key":"B53","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11306-019-1543-0","article-title":"Metabolomics reveals elevated urinary excretion of collagen degradation and epithelial cell turnover products in irritable bowel syndrome patients","volume":"15","author":"Yamamoto","year":"2019","journal-title":"Metabolomics"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jand.2012.04.016","article-title":"The automated self-administered 24-hour dietary recall (ASA24): a resource for researchers, clinicians, and educators","volume":"112","author":"Subar","year":"2012","journal-title":"J Acad Nutr Diet"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00016.2023","article-title":"IBS randomized crossover challenge study: FODMAPs alter bile acids, phenolic- and tryptophan metabolites, while gluten modifies lipid metabolism","volume":"325","author":"Nordin","year":"2023","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3390\/nu14030635","article-title":"Performance of the digital dietary assessment tool MyFoodRepo against a weighed food diary","volume":"14","author":"Zuppinger","year":"2022","journal-title":"Nutrients"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.10.877","article-title":"Mediators and moderators of treatment effects in randomized clinical trials","volume":"59","author":"Kraemer","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2003.08.009","article-title":"Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test","volume":"57","author":"Brookes","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-024-08672-7","article-title":"Digital health interventions are effective for irritable bowel syndrome self-management: a systematic review","volume":"70","author":"D'Silva","year":"2025","journal-title":"Dig Dis Sci"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e24134","DOI":"10.2196\/24134","article-title":"A novel mobile app (Heali) for disease treatment in participants with irritable bowel syndrome: randomized controlled pilot trial","volume":"23","author":"Rafferty","year":"2021","journal-title":"J Med Internet Res"},{"key":"B61","doi-asserted-by":"publisher","first-page":"100891","DOI":"10.1016\/j.imu.2022.10089110","article-title":"The impact of artificial intelligence algorithms on management of patients with irritable bowel syndrome: a systematic review","volume":"29","author":"Kordi","year":"2022","journal-title":"Inform Med Unlocked"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202308313","article-title":"Cross-cohort gut microbiome signatures of irritable bowel syndrome presentation and treatment","volume":"11","author":"Li","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.634511","article-title":"Applications of machine learning in human microbiome studies: feature selection, biomarker identification, disease prediction and treatment","volume":"12","author":"Marcos-Zambrano","year":"2021","journal-title":"Front Microbiol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40168-017-0267-5","article-title":"Optimizing methods and dodging pitfalls in microbiome research","volume":"5","author":"Kim","year":"2017","journal-title":"Microbiome"},{"key":"B65","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1038\/s41467-022-33071-9","article-title":"Batch effects removal for microbiome data via conditional quantile regression (ConQuR)","volume":"13","author":"Ling","year":"2022","journal-title":"Nat Commun"},{"key":"B66","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13059-021-02306-1","article-title":"Microbiome meta-analysis and cross-disease comparison enabled by the SIAMCAT machine learning toolbox","volume":"22","author":"Wirbel","year":"2021","journal-title":"Genome Biol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2489074","article-title":"Best practices for developing microbiome-based disease diagnostic classifiers through machine learning","volume":"17","author":"Li","year":"2025","journal-title":"Gut Microbes"},{"key":"B68","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s41512-022-00136-8","article-title":"Targeted validation: validating clinical prediction models in the intended population and setting","volume":"6","author":"Sperrin","year":"2022","journal-title":"Diagn Progn Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/frai.2022.872720","article-title":"A unified framework on generalizability of clinical prediction models","volume":"5","author":"Wan","year":"2022","journal-title":"Front Artif Intell"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.121.008487","article-title":"External validation of clinical prediction models: a scoping review of the literature","volume":"15","author":"Gulati","year":"2022","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70056","article-title":"A practical guide to SHAP analysis: explaining supervised machine learning predictions and best practices","volume":"17","author":"Ponce-Bobadilla","year":"2024","journal-title":"Clin Transl Sci"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-082505","article-title":"PROBAST+AI: an updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods","volume":"388","author":"Moons","year":"2025","journal-title":"BMJ"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1034-x","article-title":"CONSORT-AI extension: reporting guidelines for clinical trial reports for interventions involving artificial intelligence","volume":"26","author":"Liu","year":"2020","journal-title":"Nat Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1037-7","article-title":"SPIRIT-AI extension: guidelines for clinical trial protocols for interventions involving artificial intelligence","volume":"26","author":"Cruz Rivera","year":"2020","journal-title":"Nat Med"},{"key":"B76","volume-title":"Irritable bowel syndrome in adults: diagnosis and management (CG61)","year":"2008"},{"key":"B77","volume-title":"Irritable bowel syndrome in adults: quality standard (QS114)","year":"2016"},{"key":"B78","volume-title":"Ethics and governance of artificial intelligence for health","year":"2021"},{"key":"B79","volume-title":"Ethics and governance of artificial intelligence for health: guidance on large multi-modal models","year":"2025"},{"key":"B80","volume-title":"Good machine learning practice for medical device development: guiding principles","year":"2025"},{"key":"B81","article-title":"Regulation (EU) 2016\/679 (General Data Protection Regulation). Article 9: processing of special categories of personal data","volume-title":"Official Journal of the European Union","year":"2016"},{"key":"B82","volume-title":"Questions and answers on the interplay between the Clinical Trials Regulation and the General Data Protection Regulation","year":"2019"},{"key":"B83","volume-title":"Marketing submission recommendations for a predetermined change control plan for artificial intelligence-enabled device software functions: guidance for industry and Food and Drug Administration staff","year":"2025"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1809221\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:50:25Z","timestamp":1780030225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1809221\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":83,"alternative-id":["10.3389\/fimmu.2026.1809221"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1809221","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"article-number":"1809221"}}